T
Tobira Therapeutics
A biotechnology company engaging in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious…
About Tobira Therapeutics
Tobira Therapeutics, Inc. operated as a clinical-stage biopharmaceutical company, established in 2006 with a strategic focus on therapies for liver disease, fibrosis, and HIV-1. The company's business model centered on the development and eventual commercialization of pharmaceutical assets, with its lead product candidate being cenicriviroc (CVC). This drug is an orally administered immunomodulator designed as a dual antagonist of the CCR2 and CCR5 chemokine receptors, which are implicated in inflammatory and fibrotic disease pathways.
The company's primary therapeutic target for CVC was non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease with no approved treatments, which can lead to cirrhosis and liver failure. Tobira initiated the CENTAUR Phase 2b clinical trial to assess CVC's efficacy in adults with NASH and liver fibrosis. While the study did not meet its primary endpoint, it demonstrated a statistically significant improvement in fibrosis without the worsening of NASH, a key secondary endpoint that supported further development. This ultimately led to the design of the global AURORA Phase 3 trial. CVC was also positioned as a potential treatment for HIV-1, having completed Phase 2 trials demonstrating its safety profile in infected subjects.
Dr. Laurent Fischer, a seasoned executive with extensive experience in liver disease and virology at companies like Hoffmann-La Roche and DuPont-Merck, led Tobira as its Chief Executive Officer from March 2014. His background includes the successful launch of major HIV therapies, which was highly relevant to Tobira's dual-pipeline strategy. A significant milestone in the company's history occurred in November 2016, when it was acquired by Allergan plc (now part of AbbVie) in a deal valued at up to $1.7 billion. The acquisition integrated CVC and another pipeline asset, evogliptin, into Allergan's gastroenterology research and development portfolio, aiming to create a leading position in the burgeoning NASH market.
Source: Dealroom company dataNews
Open roles
Tobira Therapeutics in the Manalapan Township ecosystem
The Tobira Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Frazier Healthcare Partners
Canaan- MPMontreux Equity Partners
Domain Associates
Series B and later2 investors entered at this stage
RMI Partners
Oxford Finance
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tobira Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tobira Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

